In the second episode of our prostate-cancer series, we investigate the inevitability of castration resistance: the biochemical, radiological and clinical progression of prostate cancer despite the best efforts of the heroic MDT. While this space will likely change in the coming years, with many novel anti-androgen agents displaying efficacy in the HSPC space, the current standards of care for patients include docetaxel and the dynamic duo of abiraterone + prednisolone and enzalutamide. These latter two agents are frequently used in the first line when a patient cannot or is unlikely to tolerate docetaxel chemotherapy.

However, there can only be one Lord of the Anti-Androgens, and today Josh and Michael will reveal their preferred agent. Listen on to find out which, and please, contain your excitement.

Links to studies discussed in this episode (subscription may be required):

1. PREVAIL: https://www.nejm.org/doi/full/10.1056/nejmoa1405095
2. COU-AA-302: https://www.nejm.org/doi/full/10.1056/nejmoa1209096
3. TAX-327 (cameo only): https://www.nejm.org/doi/full/10.1056/nejmoa040720

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.